Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
22 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
19
19 articles ont été cités au moins 19fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 097
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
33
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
25
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Artemisia annua Aqueous Extract as a Biocidal Agent against Alphitobius diaperinus Beetles in Poultry Litter
2026ArticleEuropean Journal of Medicinal Plants
T-A-Φ and J-A-Φ formulations for efficient electromagnetic simulations of High-Temperature Superconductors in 2D
2025ArticleSuperconductor Science and Technology
Herbal Mixtures: Aspects Related to the Quality of Chinese Medicine Formulas and Perspectives for Products Registration in Brazil
2021ArticleEuropean Journal of Medicinal Plants
HTS Coated conductor losses model using the coupling method and the T-A formulation
2021Congrès7th International Workshop on Numerical Modelling of High Temperature Superconductors (HTS 2020)
Antimicrobial Effect of Arrabidaea chica Polyphenolic Extract Used as Dentin Pre-treatment against Cariogenic Microbiota
2020ArticleEuropean Journal of Medicinal Plants
Survey on Non-Human Primates and Mosquitoes Does not Provide Evidences of Spillover/Spillback between the Urban and Sylvatic Cycles of Yellow Fever and Zika Viruses Following Severe Outbreaks in Southeast Brazil
2020ArticleViruses
Nitrogen Nutrition in Dry Tropical Forest at Different Times of Regeneration
2019ArticleJournal of Experimental Agriculture International
Temporal and spatial control of fungal filamentous growth in Candida albicans
2018Thèse
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR MARIA DE OLIVEIRA
2 RUE BOILEAU, 92120 MONTROUGE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
JAMA · 2025
ImportanceHigh-flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) are commonly used respiratory support therapies for patients with acute respiratory failure (ARF).ObjectiveTo assess whether HFNO is noninferior to NIV on the rates of endotracheal intubation or death at 7 days in 5 patient groups with ARF.Design, Setting, and ParticipantsThis noninferiority, randomized clinical trial enrolled hospitalized adults (aged ≥18 years; classified as 5 patient groups with ARF: nonimmunocompromised with hypoxemia, immunocompromised with hypoxemia, chronic obstructive pulmonary disease [COPD] exacerbation with respiratory acidosis, acute cardiogenic pulmonary edema [ACPE], or hypoxemic COVID-19, which was added as a separate group on June 26, 2023) at 33 hospitals in Brazil between November 2019 and November 2023 (final follow-up: April 26, 2024).InterventionsHigh-flow nasal oxygen (n = 883) or NIV (n = 883).Main Outcomes and MeasuresThe primary outcome was endotracheal intubation or death within 7 days assessed using a bayesian hierarchical model with dynamic borrowing across patient groups. Noninferiority was defined by a posterior probability of 0.992 or greater for an odds ratio (OR) less than 1.55.ResultsAmong 1800 patients, 1766 completed the study (mean age, 64 [SD, 17] years; 707 [40%] were women). The primary outcome of endotracheal intubation or death at 7 days occurred in 39% (344/883) in the HFNO group vs 38% (336/883) in the NIV group. In the immunocompromised with hypoxemia patient group, the primary outcome occurred in 57.1% (16/28) in the HFNO group vs 36.4% (8/22) in the NIV group; enrollment was stopped for futility (final OR, 1.07; 95% credible interval [CrI], 0.81-1.39; noninferiority posterior probability [NPP], 0.989). In the nonimmunocompromised with hypoxemia group, the primary outcome occurred in 32.5% (81/249) in the HFNO group vs 33.1% (78/236) in the NIV group (OR, 1.02 [95% CrI, 0.81-1.26]; NPP, 0.999). In the ACPE group, the primary outcome occurred in 10.3% (14/136) in the HFNO group vs 21.3% (29/136) in the NIV group (OR, 0.97 [95% CrI, 0.73-1.23]; NPP, 0.997). In the hypoxemic COVID-19 group, the primary outcome occurred in 51.3% (223/435) in the HFNO group vs 47.0% (210/447) in the NIV group (OR, 1.13 [95% CrI, 0.94-1.38]; NPP, 0.997). In the COPD exacerbation with respiratory acidosis group, the primary outcome occurred in 28.6% (10/35) in the HFNO group vs 26.2% (11/42) in the NIV group (OR, 1.05 [95% CrI, 0.79-1.36]; NPP, 0.992). However, a post hoc analysis without dynamic borrowing across the 5 ARF patient groups revealed some qualitatively different results in patients with COPD, immunocompromised patients, and patients with ACPE. The incidence of serious adverse events was similar (9.4% of patients in HFNO group vs 9.9% in NIV group).Conclusions and RelevanceCompared with NIV, HFNO met prespecified criteria for noninferiority for the primary outcome of endotracheal intubation or death within 7 days in 4 of the 5 patient groups with ARF. However, the small sample sizes in some patient groups and the sensitivity of the findings to the choice of analysis model suggests the need for further study in patients with COPD, immunocompromised patients, and patients with ACPE.Trial RegistrationClinicalTrials.gov Identifier: NCT03643939
Tropical medicine & international health : TM & IH · 2025
ABSTRACTObjectivesThis study aimed to investigate the social and economic impacts and disease burden of Chikungunya Fever globally through a systematic literature review.MethodsWe performed a comprehensive literature search through MEDLINE (via PubMed), LILACS, and Embase databases, and grey literature, including studies of populations diagnosed with Chikungunya Fever or at risk of infection published in English, Spanish, French, or Portuguese, without date restrictions. Two reviewers independently performed study selection, data extraction, and quality assessment. Methodological quality was assessed using different tools.ResultsForty‐three publications were included. Until 2013, publications originated solely from the Asian and African continents. From 2015 onwards, South America emerged as the predominant source. Publications were classified as cost studies (25), including cost‐of‐illness (18) and program cost (6); burden of disease studies (10); cost‐outcome studies (4), including cost‐effectiveness (3) and cost‐utility (1); and quality‐of‐life studies (15). Reported total direct costs associated with Chikungunya Fever ranged from US$ 3.5 million (US Virgin Islands, 2014–2015) to US$ 83.6 billion (Region of the Americas, 2013–2015). Direct medical costs varied from US$ 308.94 (Tamil Nadu, India, 2006) to US$ 33.7 million (Réunion Island, 2005–2006). Vector control program costs ranged from US$ 888,000 annually (Greece, 2013–2017) to US$ 466 million (Brazil, 2016). Estimated disability‐adjusted life years per 100,000 population ranged from 4.53 (India, 2006) to 2432 (Region of the Americas, 2013–2015). Quality‐of‐life studies demonstrated substantial declines across multiple domains, indicating significant functional impairment due to Chikungunya Fever.ConclusionChikungunya Fever imposes a considerable economic and social burden, surpassing that of other endemic arboviral diseases such as dengue and yellow fever. These findings underscore the need for further research to accurately quantify the full scope of Chikungunya Fever‐related costs and impacts on affected populations.
Nutrients · 2025
Background/Objectives: Yacon syrup (Smallanthus sonchifolius) has gained attention due to its high concentration of fructooligosaccharides (FOSs) and associated health benefits. This systematic review aimed to evaluate the effects of yacon syrup on metabolic parameters and intestinal health in humans over the last decade. Methods: Following PRISMA guidelines, we conducted a systematic search in databases, including Medline (PubMed), Science Direct, Embase, Scopus, and SciELO, up to October 2024. Inclusion criteria focused on clinical trials examining the impact of yacon syrup on glycemic control, lipid profile, insulin sensitivity, appetite regulation, and gut microbiota in healthy, overweight, or obese individuals. Seven studies met the inclusion criteria, encompassing 161 participants from diverse populations. Results: Yacon syrup supplementation demonstrated significant reductions in fasting insulin, HOMA-IR, and LDL cholesterol, alongside improvements in satiety and intestinal transit time. Acute supplementation with yacon syrup had inconsistent results for postprandial glycemia and insulin levels, probably due to prior individual gut microbiota composition. Longer interventions with yacon syrup were associated with enhanced microbiota modulation and appetite regulation, particularly in women. Mild gastrointestinal discomfort was reported, but with the continued use of yacon syrup, the symptoms decreased. Yacon syrup presents promising health benefits, including improved insulin sensitivity, weight management, and gut health. However, further research is needed to establish optimal dosing and long-term safety. Conclusions: This review highlights the potential of yacon syrup as a functional supplement for metabolic and gastrointestinal health.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases · 2026 · Journal Article
Pereira ACEDS, Gallo LG, Oliveira AFM, de Oliveira MRF, et al.
Pharmaceuticals (Basel, Switzerland) · 2026 · Journal Article
Torchelsen FKVDS, Lages EB, de Oliveira MA, Barros ALB, et al.
Respiratory medicine · 2026 · Journal Article
Da Conceição Soares F, de Morais Lima JH, Pedrosa R, Arcoverde VAT, et al.
Brazilian journal of veterinary medicine · 2025 · Case Reports
Aya-Cuero CA, Pardo-Moreno YA, León-Aguilar LK, Cruz-Ochoa PF, et al.
Vox sanguinis · 2025 · Journal Article
Brunetta DM, Carvalho LEM, Beserra NM, Lima CMF, et al.
Odontology · 2025 · Journal Article
De Azevedo Queiroz ÍO, de Mello WG, Machado T, de Oliveira MCG, et al.
Aging medicine (Milton (N.S.W)) · 2024 · Journal Article
de Oliveira MCA, Andrade JP, Porto ACS, Martins GMT, et al.
Therapeutic innovation & regulatory science · 2026 · Journal Article
Rodrigues OMM, Lopes IG, de Oliveira MEF, Fragoso MAC, et al.
Tropical medicine & international health : TM & IH · 2025 · Journal Article
Pedí VD, de França GVA, Rodrigues VB, Duailibe FT, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025 · Journal Article
Pelepenko LE, de Oliveira MC, Masaro DA, Lustosa GMMM, et al.
Pain medicine (Malden, Mass.) · 2026 · Journal Article
de Souza G, Daux Buffon L, Hardt da Silva R, Galassi TO, et al.
JAMA · 2025 · Equivalence Trial
RENOVATE Investigators and the BRICNet Authors, Maia IS, Kawano-Dourado L, Tramujas L, et al.
Geriatric nursing (New York, N.Y.) · 2026 · Journal Article
de Assis LGM, Lucchetti G, Bertocchi FM, de Oliveira MM, et al.
Geriatric nursing (New York, N.Y.) · 2025 · Journal Article
Andrade JP, de Oliveira MCA, Porto ACS, Martins GMT, et al.
Environmental science and pollution research international · 2026 · Journal Article
Alshubaith IH, Alhajri S, Alhajri A, Alsultan RA, et al.
JCO global oncology · 2025 · Journal Article
da Fonseca LG, Freire CS, Guedes RAV, Lyra MC, et al.
Tropical medicine & international health : TM & IH · 2025 · Journal Article
Pedí VD, de França GVA, Rodrigues VB, Duailibe FT, et al.
Nutrients · 2025 · Journal Article
Pereira MF, Soares IC, Cabral MM, de Freitas PA, et al.
Geriatric nursing (New York, N.Y.) · 2025 · Journal Article
Andrade JP, de Oliveira MCA, Porto ACS, Martins GMT, et al.
Brazilian journal of otorhinolaryngology · 2025 · Journal Article
Luccas GMG, Marinho KS, Cardoso LC, de Oliveira MPS, et al.
Tropical medicine & international health : TM & IH · 2025 · Journal Article
Pedí VD, de França GVA, Rodrigues VB, Duailibe FT, et al.
Thrombosis research · 2024 · Journal Article
Ferreira BÁ, Danielian PLLB, Caetano GC, Ferreira CRL, et al.
Forensic science, medicine, and pathology · 2026 · Journal Article
Abuabara A, do Nascimento TVPM, da Cruz KR, Küchler EC, et al.
The Journal of nutritional biochemistry · 2026 · Journal Article
do Nascimento AC, de Albuquerque TMR, de Oliveira DG, de Oliveira AP, et al.
Nutrients · 2025 · Systematic Review
Castro FLAL, Heredia JE, Schuch LF, de Arruda JAA, et al.
JCO global oncology · 2025 · Journal Article
da Fonseca LG, Freire CS, Guedes RAV, Lyra MC, et al.
Nutrients · 2025 · Journal Article
Pereira MF, Soares IC, Cabral MM, de Freitas PA, et al.